Zombie UV™ Fixable Viability Kit

Product Details

Preparation

Zombie UV™ Fixable Viability kit is composed of lyophilized Zombie UV™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie UV™ dye until fully dissolved. 100 tests = 1 vial of Zombie UV™ + DMSO, 500 tests = 5 vials of Zombie UV™ + DMSO.

Storage & Handling

Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie UV™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser

Ultraviolet Laser (355 nm)

Application Notes

Standard Cell Staining Protocol:

1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie UV™ dye and mix until fully dissolved
3. Wash cells with PBS buffer (no Tris buffer and protein free).
4. Dilute Zombie UV™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 10⁶ cells in diluted 100 µl Zombie UV™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
   
   Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
   Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.


5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
7. Continue performing antibody staining procedure as desired.
8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

1. Wash cells with PBS buffer (no Tris buffer and protein free).
2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie UV™ dye and mix until fully  dissolved
3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie UV™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie UV™ solution. Resuspend 1-10 x 10⁶ cells in the appropriate volume of Zombie UV™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
   
   Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
   Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.


4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.

Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie UV™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie UV™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie UV™.

Zombie UV™ dye is excited by the UV laser (350 nm) and has fluorescence emission maximum at 459 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie UV™ dye has similar emission to DAPI.

 

Application References

1. Souza-Fonesca-Guimaraes F, et al. 2015. PNAS. 112:2376. PubMed

Product Citations

1. Zgair A, et al. 2017. Sci Rep. . 10.1038/s41598-017-15026-z. PubMed
2. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
3. Reyes RA, et al. 2021. PLoS One. 16:e0261656. PubMed
4. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
5. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
6. Souza-Fonseca-Guimaraes F, et al. 2016. Cell Death Dis. 7:e2302. PubMed
7. Lu C, et al. 2019. Cancer Immunol Res. 7:414. PubMed
8. Xu H, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.03.003. PubMed
9. Clarke F,et al. 2017. PLoS One. 10.1371/journal.pone.0186625. PubMed
10. Vaughan HJ, et al. 2021. Mol Ther Oncolytics. 21:377. PubMed
11. Matsui K, et al. 2015. PLoS One. 10: 0137195. PubMed
12. Trimaglio G, et al. 2020. Oncoimmunology. 9:1790125. PubMed
13. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
14. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
15. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
16. Souza-Fonseca-Guimaraes F, et al. 2015. Proc Natl Acad Sci U S A. 112:2376. PubMed
17. Rao S, et al. 2017. Cell. 168(3):503-516.e12. PubMed
18. Godbersen-Palmer C, et al. 2020. J Immunol. 204:2973. PubMed
19. Poggio M, et al. 2019. Cell. 177:414. PubMed
20. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
21. Leigh N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1502181. PubMed
22. An J,et al. 2017. Sci Rep.. 10.1038/s41598-017-13629-0. PubMed
23. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
24. Odeh-Couvertier VY, et al. 2022. Bioeng Transl Med. 7:e10282. PubMed
25. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
26. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
27. Lord JD, et al. 2018. Clin Immunol. 193:24:00. PubMed
28. Nath PR, et al. 2019. Cancer Immunol Res. 7:1547. PubMed
29. Fallet B, et al. 2020. Cell Rep. 30:1013. PubMed
30. Littwitz-Salomon E, Schimmer S, and Dittmer U. 2017. J Virol. 10.1128/JVI.01122-17. PubMed
31. Zhang X, et al. 2022. Cell Rep. 40:111203. PubMed
32. Reighard SD, et al. 2020. Cell Rep Med. :1. PubMed
33. Lin J, et al. 2017. Sci Rep. 7:41722. PubMed
34. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
35. Moreno-Fernandez ME, et al. 2018. JCI Insight. 3. PubMed
36. Li D, et al. 2019. J Lipid Res. 60:1503. PubMed
37. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
38. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
39. Gehling K, et al. 2022. Life Sci Alliance. 5:. PubMed
40. Nath PR, et al. 2022. Oncoimmunology. 11:2111909. PubMed
41. Trüb M, et al. 2020. J Immunother Cancer. 8:00. PubMed
42. Shiao SL, et al. 2021. Cancer Cell. 39:1202. PubMed
43. Zeng Y, et al. 2019. Oncotarget. 10:4479. PubMed
44. Fredriksson-Lidman K, et al. 2017. PLoS One. 10.1371/journal.pone.0185509. PubMed
45. Truong AS, et al. 2021. J Clin Invest. 131:. PubMed
46. Kalbasi A, et al. 2020. Sci Transl Med. :12. PubMed
47. Huang SSY, et al. 2021. Biology. 10(8):. PubMed
48. O’Neill R, et al. 2017. J Immunol. 10.4049/jimmunol.1700380. PubMed
49. Harder I, et al. 2022. Cells. 11:. PubMed
50. McVey JC, et al. 2022. iScience. 25:103847. PubMed
51. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
52. Burns JC, et al. 2020. eLife. 9:00. PubMed
53. Smith CA, et al. 2019. JCI Insight. 4. PubMed
54. Den Braanker H, et al. 2021. Front Immunol. 12:768113. PubMed
55. Ganguly S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:891. PubMed
56. Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed
57. Johnston S, et al. 2021. Elife. 10: . PubMed
58. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
59. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
60. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
61. Graciotti M, et al. 2020. Vaccines (Basel). 8:00. PubMed
62. Capuccini B, et al. 2016. Sci Rep. 6:39258. PubMed
63. Lyle C, et al. 2019. Sci Rep. 9:20257. PubMed
64. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
65. Moreno-Fernandez ME, et al. 2021. STAR Protoc. 2:100937. PubMed
66. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
67. Georg P, et al. 2022. Cell. 185:493. PubMed
68. Ireland RE, et al. 2022. Viruses. 14:. PubMed
69. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
70. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
71. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
72. Nath PR, et al. 2019. Front Immunol. 9:2985. PubMed
73. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
74. Mempin M, et al. 2021. Cancers (Basel). 13:. PubMed
75. Wimmers F, et al. 2021. Cell. 184:3915. PubMed
76. Galván-Peña S, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
77. Salehi S, et al. 2017. PLoS One. 10.1371/journal.pone.0163614. PubMed
78. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
79. Prosser A, et al. 2021. STAR Protoc. 2:100810. PubMed
80. Grabiec A, et al. 2017. J Allergy Clin Immunol. 10.1016/j.jaci.2017.03.024. PubMed
81. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
82. Lee A, et al. 2022. Nat Commun. 13:549. PubMed
83. Giles D, et al. 2016. PLoS One. 11: 0149783. PubMed
84. Lacar B, et al. 2016. Nat Commun. 7: 11022. PubMed
85. Zeng Y, et al. 2019. FASEB J. 33:6596. PubMed
86. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
87. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
88. Zhong W, et al. 2022. Front Immunol. 13:1001255. PubMed
89. Gamradt S, et al. 2021. iScience. 24:103312. PubMed

Antigen Details

Biology Area

Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience

Gene ID

NA

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.

Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.

How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?

We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.

Can I use Zombie with cells suspension containing serum?

Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.

Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Certificate of Analysis